|

Almonertinib Clinical Trials

8 actively recruiting trials

Also known as: Anlotinib, HS-10296, ctDNA dynamic monitoring guided the Almonertinib treatment

Pipeline

Phase 2: 2Phase 3: 5Phase 1/2: 1

Top Sponsors

  • Sun Yat-sen University2
  • Sichuan University1
  • Shanghai Cancer Hospital, China1
  • Qianfoshan Hospital1
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.1

Indications

  • Cancer8
  • Lung Cancer6
  • Non Small Cell Lung Cancer3
  • EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor1
  • EGFR Activating Mutation1

Other8 trials

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
Phase 3
A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/2
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Phase 2
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
Phase 3
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
Phase 3
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases
Phase 3
MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.
Phase 3
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.